Drug
Tovorafenib clinical trials
Also written TAK-580, MLN2480 and Ojemda.
- studies test it
- 13
- open now
- 6
- in phase 3
- 1
- first study started
- 2011
Keep track of what changes. Save the tovorafenib studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Brand
Studies by the year they started
12 studies that test it; most in 2021 (2); 1 more planned to start later
| Year | Studies |
|---|---|
| 2011 | 1 |
| 2016 | 1 |
| 2018 | 1 |
| 2021 | 2 |
| 2022 | 2 |
| 2023 | 1 |
| 2024 | 2 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 1
- Phase 1
- 6
- Phase 2
- 6
- Phase 3
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 7 · Other 6
Day One Biopharmaceuticals, Inc. (4) · Millennium Pharmaceuticals, Inc. (2) · National Cancer Institute (NCI) (2) · Ipsen (1) · Karen D. Wright, MD (1) · Nationwide Children's Hospital (1) · Sabine Mueller, MD, PhD (1) · Daniel Morgenstern (1)
Often tested with
Tested in the same studies.
Vinblastine (1) · Pimasertib (1) · Plozalizumab (1) · Vedolizumab (1) · Ipilimumab (1)
Studies
Open first, then newest update. How each study uses tovorafenib is read from its arms, and is right about nine times in ten.
Testing it · 13
- A Study With Tovorafenib (DAY101) as a Treatment Option for Progressive, Relapsed, or Refractory Langerhans Cell HistiocytosisRecruitingPhase 2National Cancer Institute (NCI)NCT05828069Written as Tovorafenib
- Study of Tovorafenib in High-Grade Glioma and Diffuse Intrinsic Pontine Glioma (DIPG)Not yet recruitingPhase 2Nationwide Children's HospitalNCT07206849Written as Tovorafenib
- Testing the Combination of Anti-cancer Drugs, Tovorafenib Plus Rituximab, in Patients With Hairy Cell LeukemiaRecruitingPhase 1/2National Cancer Institute (NCI)NCT06965114Written as Tovorafenib
- Tovorafenib for Treatment of Craniopharyngioma in Children and Young AdultsRecruitingPhase 2Sabine Mueller, MD, PhDNCT05465174Written as Tovorafenib
- Pilot Study of Vinblastine and Tovorafenib in Pediatric Patients With Recurrent/Progressive RAF Altered Low Grade GliomasRecruitingEarly Phase 1Daniel MorgensternNCT06381570Written as Tovorafenib
- A Study to Evaluate Tovorafenib in Pediatric and Young Adult Participants With Relapsed or Progressive Low-Grade Glioma and Advance Solid TumorsRecruitingPhase 2Day One Biopharmaceuticals, Inc.NCT04775485Written as Tovorafenib
- DAY101 vs. Standard of Care Chemotherapy in Pediatric Participants With Low-Grade Glioma Requiring First-Line Systemic Therapy (LOGGIC/FIREFLY-2)Active, not recruitingPhase 3Day One Biopharmaceuticals, Inc.NCT05566795Written as Tovorafenib
- A Study to Assess a Medicine Called Tovorafenib in Japanese Children and Young Adults With Brain TumoursActive, not recruitingPhase 1IpsenNCT07441707Written as Tovorafenib
- DAY101 In Gliomas and Other TumorsCompletedPhase 1Karen D. Wright, MDNCT03429803Written as DAY101
- Tovorafenib (DAY101) Monotherapy for Patients With Melanoma and Other Solid TumorsTerminatedPhase 2Day One Biopharmaceuticals, Inc.NCT04985604Written as Tovorafenib
- Tovorafenib (DAY101) or in Combination With Pimasertib for Participants With Melanoma and Other Solid TumorsTerminatedPhase 1Day One Biopharmaceuticals, Inc.NCT07121829Written as Tovorafenib
- Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of Investigational Treatments in Combination With Standard of Care Immune Checkpoint Inhibitors in Participants With Advanced MelanomaTerminatedPhase 1Millennium Pharmaceuticals, Inc.NCT02723006Written as TAK-580
- Study of MLN2480 in Participants With Relapsed or Refractory Solid Tumors Followed by a Dose Expansion in Participants With Metastatic MelanomaCompletedPhase 1Millennium Pharmaceuticals, Inc.NCT01425008Written as MLN2480
Given in every arm · 1 — tovorafenib is usual care beside what is tested
Codes
What other systems call tovorafenib · ClinicalTrials.gg INT000905
- MeSH (NLM) C000626518tovorafenibConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) ZN90E4027MTOVORAFENIBConfirmed FDA, NLM
- NCI Thesaurus C106254TovorafenibOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000626518 | tovorafenib | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | ZN90E4027M | TOVORAFENIB | Confirmed FDA, NLM |
| NCI Thesaurus | C106254 | Tovorafenib | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.